Cargando…
A novel peptide therapeutic targeting PD1 immune checkpoint with equipotent antagonism of both ligands and a potential for better management of immune-related adverse events
Autores principales: | Sasikumar, Pottayil, Shrimali, Rajeev, Adurthi, Sreenivas, Ramachandra, Raghuveer, Satyam, Leena, Dhudashiya, Amit, Samiulla, Dodheri, Sunilkumar, K B, Ramachandra, Murali |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3991264/ http://dx.doi.org/10.1186/2051-1426-1-S1-O24 |
Ejemplares similares
-
PD-1 derived CA-170 is an oral immune checkpoint inhibitor that exhibits preclinical anti-tumor efficacy
por: Sasikumar, Pottayil G., et al.
Publicado: (2021) -
Small Molecule Agents Targeting PD-1 Checkpoint Pathway for Cancer Immunotherapy: Mechanisms of Action and Other Considerations for Their Advanced Development
por: Sasikumar, Pottayil G., et al.
Publicado: (2022) -
Discovery of indole tetrafluorophenoxymethylketone-based potent novel small molecule inhibitors of caspase-3
por: Samiulla, Dodheri Syed, et al.
Publicado: (2012) -
MON-365 Immune Checkpoint Inhibitors: Endocrinopathies and Severe Electrolyte Abnormalities
por: El Mais, Rania, et al.
Publicado: (2019) -
Comparison of equipotent doses of rocuronium and vecuronium
por: Parasa, Mrunalini, et al.
Publicado: (2015)